Daiichi Sankyo to Launch Memary® 5mg, 10mg and 20mg Tablets
for the Treatment of Alzheimer’s Disease

TOKYO, Japan (April 27, 2011) — Daiichi Sankyo Company, Limited today announced that it will launch Memary® 5mg, 10mg and 20mg Tablets (generic name: Memantine Hydrochloride, Approval to Manufacture and Market: January 21) given once daily for the treatment of moderate to severe Alzheimer's Disease on Wednesday, June 8.

The launch in Japan of Memary® had previously been postponed on March 16 following the Tohoku Pacific Offshore Earthquake.

###